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Abstract
Background Gentamicin has historically been used prior to insertion and removal of indwelling urinary
catheters (IDCs) around elective joint replacement surgery to prevent infection; however, this indication is
not recognized in the Australian Therapeutic Guidelines: Antibiotic and the paradigm for safe use of gentamicin
has shifted.
Methods The antimicrobial stewardship team of a 500 bed tertiary regional hospital performed a
retrospective clinical study of gentamicin IDC prophylaxis around total hip and knee arthroplasties. Results
were presented to the orthopaedic surgeons. A literature review identified no guidelines to support gentamicin
prophylaxis and only a very low risk of bacteraemia associated with IDC insertion/removal in patients with
established bacteriuria. Consensus was reached with the surgeons to discontinue this practice. Subsequent
prospective data collection was commenced to determine effectiveness, with weekly feedback to the
Department Head of Orthopaedics.
Results Data from 137 operations pre-intervention (6 months) were compared with 205 operations post-
intervention (12 months). The median patient age was 72 years in both groups. Following the intervention,
reductions in gentamicin use were demonstrated for IDC insertion (59/137 (42%) to 4/205 (2%), P < 0.01)
and removal (39/137 (28%) to 6/205 (3%), P < 0.01). No gentamicin use was observed during the final 40
weeks of the post-intervention period. There were no significant differences between the groups for pre-
operative bacteriuria, surgical site infections or acute kidney injury.
Conclusion A collaborative approach using quality improvement methodology can lead to an evidence-based
reappraisal of established practice. Regular rolling audits and timely feedback were useful in sustaining change.
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Gentamicin has historically been used prior to insertion and removal of indwelling urinary 
catheters (IDCs) around elective joint replacement surgery to prevent infection; however, this 
indication is not recognised in the Australian Therapeutic Guidelines: Antibiotic and the 
paradigm for safe use of gentamicin has shifted.  
Methods:  
The antimicrobial stewardship team of a 500 bed tertiary regional hospital performed a 
retrospective clinical study of gentamicin IDC prophylaxis around total hip and knee 
arthroplasties. Results were presented to the orthopaedic surgeons. A literature review 
identified no guidelines to support gentamicin prophylaxis and only a very low risk of 
bacteraemia associated with IDC insertion/removal in patients with established bacteriuria. 
Consensus was reached with the surgeons to discontinue this practice. Subsequent 
prospective data collection was commenced to determine effectiveness, with weekly 
feedback to the Department Head of Orthopaedics.  
Results:  
Data from 137 operations pre-intervention (6 months) were compared with 205 operations 
post-intervention (12 months). The median patient age was 72 years in both groups.  
Following the intervention, reductions in gentamicin use were demonstrated for IDC insertion 
(59/137 [42%] to 4/205 [2%], p<0.01) and removal (39/137 [28%] to 6/205 [6%], p<0.01). No 
gentamicin use was observed during the final 40 weeks of the post-intervention period. 
There were no significant differences between the groups for pre-operative bacteriuria, 




A collaborative approach using quality improvement methodology can lead to an evidence 
based reappraisal of established practice. Regular rolling audits and timely feedback were 
useful in sustaining change. 
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Urinary catheterisation is common during the peri-operative period and is associated with 
increased risk of bacteriuria and symptomatic urinary tract infection (UTI).1 In contrast, 
bacteraemia from indwelling urinary catheter (IDC) manipulation is rare, even when 
indwelling times are longer.2-4 A causal link has not been established between peri-operative 
asymptomatic bacteriuria, bacteraemia and subsequent haematogenous seeding of the 
prosthetic joint.5 Studies have reported either no effect 6 or modest reduction7-13 in rates of 
bacteriuria and UTIs from antibiotic prophylaxis around short term IDC use. Several 
limitations applied: small sample sizes, none examined aminoglycosides, and the effect on 
antibiotic resistance was not routinely examined. In addition, the studies were not performed 
in the setting of orthopaedic surgery, and did not examine the impact on surgical site 
infections (SSIs).  
Gentamicin is an aminoglycoside antibiotic administered intravenously for the 
treatment of Gram-negative infections.14 Gentamicin is also recommended as prophylaxis for 
surgery with high risk of Gram-negative infections, such as urological procedures.15 Due to 
concerns over side effects such as ototoxicity and nephrotoxicity, with even after a single 
dose,16, 17 there has been a shift in the paradigm of safe gentamicin use.18 Two recent 
studies examining the combination of gentamicin with a beta-lactam antibiotic for 
orthopaedic surgical prophylaxis gave conflicting results on the risk of acute kidney injury 
(AKI).19, 20 Both highlighted the presence of additional potentially nephrotoxic factors (e.g. 
older age, fractures, volume loss, anti-hypertensive medications and analgesics).   
The Australian Therapeutic Guidelines: Antibiotic15 recommend against the routine 
use of gentamicin in the setting of peri-operative IDC insertion and removal and this 
recommendation has not changed in the latest update.21 Despite guideline 
recommendations, gentamicin had been used as peri-operative prophylaxis in around one 
third of orthopaedic patients in our hospital. Some surgeons were initially reluctant to 
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abandon gentamicin use, due to concerns about a potential increase in SSI rates and 
medico-legal considerations related to not following an established historical practice.  
Education and quality improvement are fundamental aspects of antimicrobial 
stewardship (AMS) in hospitals. 22 Recent evidence suggests that feedback as a component 
of the change management process is more effective when it is: frequently presented; 
delivered by a peer; and aims to decrease a specific behaviour. 23 Our study analysed the 
effect of education with rapid-cycle audit and feedback, a method that may be effective 
where clinicians have previously agreed to review their practice.24 The importance of 
engaging with stable staff groups such as consultant surgeons and anaesthetists became 
evident. We assessed the impact of a group of interventions that aimed to reduce 
prophylactic gentamicin use during IDC insertion and removal in orthopaedic surgery, 
without increasing SSI rates. We aspired that this quality improvement initiative could 








We initially performed a retrospective clinical study at Wollongong Hospital, a regional 500 
bed university teaching hospital in New South Wales (NSW), Australia. The antimicrobial 
stewardship (AMS) team (pharmacist and infectious diseases physician) identified the use of 
gentamicin as prophylaxis for IDC insertion and removal during a routine retrospective audit 
of systemic antibiotic prophylaxis around total hip and knee arthroplasties and revisions. IDC 
use was routine in this setting. The decision to administer gentamicin and its dose were at 
the discretion of the surgeon and there was not a departmental policy. 
Intervention 
This study employed Plan, Do, Study, Act (PDSA) quality improvement methodology25. The 
timeline of observations and interventions is shown in Figure 1. The guideline 
recommendations for routine surgical prophylaxis were the same for both the pre- and post-
intervention groups (cephazolin routinely, with or without vancomycin following risk 
assessment for methicillin-resistant Staphylococcus aureus [MRSA]).15 Notably, there was 
discussion with the surgeons and anaesthetists around guideline-concordant prescribing 
during the time interval (March 2012 to January 2013) from the presentation of initial findings 
until the main intervention point. Discussion also occurred at the AMS committee meetings 
(which included a surgeon representative) during this time. 
SSIs were defined according to standard definitions26 and reported by mandate to the 
NSW Ministry of Health. AKI was defined by the Kidney Disease Improving Global Outcomes 
criteria as a >50% rise above baseline serum creatinine.27 Assessment for vestibular toxicity 




The effect of the intervention was assessed using the following measures: prevalence of 
gentamicin use for insertion and removal of IDCs; comparative SSI rates; proportion of 
patients with AKI 48-72 hours post-operation. 
Data sources 
A retrospective dataset of total hip and total knee arthroplasties was obtained from medical 
records for the period 1 January to 30 June 2011. Gentamicin use was assessed from 
anaesthetic and medication charts, and serum creatinine measurements were retrieved from 
the electronic medical record (eMR; Cerner Powerchart™). Arthroplasty data were collected 
prospectively during the post-intervention period (February 2013 to February 2014) from the 
eMR and ward list. The infection control service provided SSI rates.  
Statistical analyses 
Statistical analyses were performed using Stata statistical software: Release 14 (Statacorp 
LP, College Station, TX, USA). Chi-square and Fisher’s exact tests were used as 
appropriate. A Shapiro-Wilk test was used to check for normal distribution, and Mann-
Whitney U-test was used for continuous variables. Statistical significance was accepted as 
p<0.05.  
Ethics 
This study was approved by the University of Wollongong and Illawarra Shoalhaven Local 





Data from 137 operations pre-intervention (6 months, retrospective) were compared with 205 
operations post-intervention (12 months, prospective; Table 1). Patient age and weight were 
similar in both groups; however, there were marginally more males in the post-intervention 
sample (31% vs. 42%, p=0.048). There were more positive pre-operative MRSA screening 
cultures in the pre-intervention group (3% vs. 0.5%, p=0.047). No differences were observed 
in the number of positive pre-operative urine samples (Table 1). Gentamicin doses ranged 
from 80mg to 240mg. 
A significant reduction in gentamicin use was demonstrated post-intervention (Table 
2). From week 12 of the post-intervention period (Figure 2), no further doses of gentamicin 
were administered for IDC manipulation.  
No significant differences were found between the numbers of superficial hip, deep 
hip, superficial knee, or deep knee infections (Table 2). There were no significant changes in 





Our study showed that a combined intervention of education and discussion with audit and 
timely feedback was effective in withdrawing the practice of prophylactic gentamicin for IDC 
insertion and removal in orthopaedic surgery. No significant changes were observed in the 
rates of SSI or AKI, although the study was not powered adequately to detect those. Most 
importantly, this study offers a model for a sustained quality improvement initiative in the 
setting of limited background data and contributes to emerging evidence on the beneficial 
role of AMS in improving antibiotic use. 
The majority of infections in orthopaedic surgery are caused by Gram-positive skin 
flora, for which cephazolin and vancomycin (where appropriate) provide adequate 
prophylaxis.15 The potential risks and lack of clinical benefit from gentamicin in this setting 
formed the basis of our intervention. Rates of gentamicin use were reducing during the 
planning and discussion period, highlighting that the ongoing interaction resulted in gradual 
practice change. This was consolidated to a withdrawal of gentamicin prescribing in the 
study sample. The importance of directly addressing medico-legal concerns and providing 
written support for practice change was also recognised.  
To our knowledge, this is the first study that has examined the impact of a change to 
IDC prophylaxis on clinical outcomes for orthopaedic surgery patients. A Cochrane review of 
antibiotic prophylaxis for short term IDC bladder drainage in adults showed that the primary 
outcome of bacteriuria was lower in the prophylaxis group.28 There is no evidence linking 
insertion and/or removal of an IDC with Gram-negative bacteraemia and seeding of a newly 
implanted prosthesis. Although a recent study has demonstrated that asymptomatic 
bacteriuria was an independent risk factor for prosthetic joint infection, preoperative antibiotic 
treatment did not show any benefit and infecting organisms were frequently different to those 
isolated prior to surgery.5 Studies reporting bacteraemia from IDCs in the setting of chronic 
catheterisation reported low rates of established infection.2-4  
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There were no deep SSIs during the pre-intervention period and only one (0.5%) 
post-intervention. During the intervening period the SSI rate was low at 1.1%, comparable 
with existing literature.29, 30 These differences were not statistically significant. Studies 
powered to detect changes in SSI rates typically require larger sample sizes.29-31 
The rate of peri-operative AKI in our study was 1-2%. Rates have been previously 
reported at 11% for orthopaedic surgeries with routine gentamicin prophylaxis, but with 
different gentamicin doses.19 The lower rate in our study may be due to the lower doses of 
gentamicin for IDC prophylaxis than for routine skin prophylaxis.  
A focus on immediate clinical outcomes (gentamicin toxicity) rather than parameters 
that appear later (antibiotic resistance) may have stronger influence on prescribing 
behaviour.32 Other strategies to reduce the risk of IDC-related UTI in the peri-operative 
setting include: intermittent or no catheterisation, early mobilisation (that shortens the period 
when the IDC needs to remain in place), training for insertion techniques, good IDC care and 
consideration of IDC materials.33 Male patients receiving epidural anaesthesia may be at 
greater risk of urinary retention in the setting of orthopaedic surgery.34-36 
There were several limitations to our study. These included confounding factors that 
may influence SSI rates (skin preparation, surgical technique, patient comorbidities) and the 
significantly larger proportion of male patients in the post-intervention sample (probably 
resulting from variation in data collection methods). The study was not powered to detect 
changes in SSI rates and those were not followed up long term, meaning that late deep 
infections may have been missed. The indication for gentamicin use was not routinely 
documented on the anaesthetic records and drug charts. The study did not follow the 
prescribing habits of individual surgeons, so some of the change in gentamicin use may 
have been due to changes in staff. There were; however, minimal staff changes at a senior 
level during study period. We believe that interpersonal interactions, the prevailing local 
culture of quality improvement and strong leadership of the units involved have contributed 
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to the successful outcomes of this study. Those features were furthermore strengthened 
during the interactive audit and feedback process; generalisability to other settings needs to 
be tested. Audiometry was not available on site to test for gentamicin toxicity. Although we 
used a methodology common in pragmatic AMS research, introduction of bias may be 
inherent, outside a randomised controlled environment.  
In conclusion, we have shown that a group of robust multi-disciplinary AMS 
interventions effected durable practice change without obvious evidence of harm. Further 
studies are required to demonstrate validity in other settings, as well as the impact of 
gentamicin prophylaxis on renal function in other types of surgery. 
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Table 1 Patient characteristics and pre-operative screening 
 Pre-intervention Post-intervention p value 
Median age, yrs 
(range) 
72 (40-91) 72 (35-87) 0.79 
Male, n (%) 43 (31) 86 (42) 0.048 







Cephazolin as skin 
prophylaxis‡, n (%) 
116/137 (87) 188/205 (92) 0.13 
Hip arthroplasty§, n (%) 58/137 (42) 70/205 (34) 0.13 
MRSA screening swab 
positive 
4/122 (3) 1/204 (0.5) 0.047 
Pathogen isolated in 
pre-operative urine 
sample║, n (%) 
25/123 (20) 28/198 (14) 0.15 
Pre-op positive urines 
treated with 
antibiotics║, n (%) 
11/25 (44) 8/28 (29) 0.24 
†
Data available from 133 patients pre-intervention; 202 post-intervention; 
‡
Data available from 134 patients pre-




Includes mixed and single pathogen growth.
 
The 




Table 2 Gentamicin use, surgical site infections and acute kidney injury, n (%) 
 Pre-intervention 
 (6 months) 




n = 605 
Post-intervention 
 (12 months) 
n = 205 
p value 
Gentamicin for 
IDC insertion  
59 (42) N/A 4 (2) <0.01 
Gentamicin for 
IDC removal†  
39 (28) N/A 6 (3) <0.01 
Surgical site 
infections, deep  








2 (2) N/A 1 (1) 0.35 
†
Data available from 137 patients pre-intervention, 204 patients post-intervention 
‡
defined as >50% rise in 











Figure 2 The proportion of patients receiving gentamicin for catheter insertion and removal over the 6 month pre-
intervention period and during each week post-intervention. The discussion and planning period is shown in grey.  
 
